89bio Inc (ETNB) - Total Liabilities
Based on the latest financial reports, 89bio Inc (ETNB) has total liabilities worth $81.75 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
89bio Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how 89bio Inc's total liabilities have evolved over time, based on quarterly financial data. See ETNB net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
89bio Inc Competitors by Total Liabilities
The table below lists competitors of 89bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fujian Star Net Communic Ltd
SHE:002396
|
China | CN¥6.68 Billion |
|
Transwarp Technology (Shanghai) Co. Ltd. A
SHG:688031
|
China | CN¥277.65 Million |
|
Shenzhen Sinexcel Electric Co Ltd
SHE:300693
|
China | CN¥2.06 Billion |
|
Bank of N.T. Butterfield & Son Ltd
NYSE:NTB
|
USA | $13.29 Billion |
|
Hilltop Holdings Inc
NYSE:HTH
|
USA | $13.39 Billion |
|
Hunan Aihua Group Co Ltd
SHG:603989
|
China | CN¥2.01 Billion |
|
Torunlar Gayrimenkul Yatirim Ortakligi AS
IS:TRGYO
|
Turkey | TL24.18 Billion |
|
Custom Truck One Source Inc
NYSE:CTOS
|
USA | $2.74 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down 89bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ETNB company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 89bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 89bio Inc (2018–2024)
The table below shows the annual total liabilities of 89bio Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $77.90 Million | +29.91% |
| 2023-12-31 | $59.96 Million | +33.27% |
| 2022-12-31 | $44.99 Million | +23.38% |
| 2021-12-31 | $36.47 Million | +349.46% |
| 2020-12-31 | $8.11 Million | +44.64% |
| 2019-12-31 | $5.61 Million | -79.55% |
| 2018-12-31 | $27.43 Million | -- |
About 89bio Inc
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly kn… Read more